Table of Content




1. Executive Summary


2. Global Myasthenia Gravis Treatment Market : Market Dynamics
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges 


3. Market Trends and Forecast Analysis from 2018 to 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Myasthenia Gravis Treatment Market Trends (2018-2023) and Forecast (2024-2030)

3.3: Global Myasthenia Gravis Treatment Market by Treatment Type
3.3.1: Cholinesterase Inhibitors
3.3.2: Chronic Immunomodulators
3.3.3: Monoclonal Antibodies
3.3.4: Rapid Immunotherapies
3.3.5: Thymectomy
3.3.6: Others

3.4: Global Myasthenia Gravis Treatment Market by End Use
3.4.1: Hospitals
3.4.2: Clinics
3.4.3: Others






4. Market Trends and Forecast Analysis by Region from 2018 to 2030
4.1: Global Myasthenia Gravis Treatment Market by Region
4.2: North American Myasthenia Gravis Treatment Market
4.2.1: North American Myasthenia Gravis Treatment Market by Treatment Type: Cholinesterase Inhibitors, Chronic Immunomodulators, Monoclonal Antibodies, Rapid Immunotherapies, Thymectomy, and Others
4.2.2: North American Myasthenia Gravis Treatment Market by End Use: Hospitals, Clinics, and Others


4.3: European Myasthenia Gravis Treatment Market
4.3.1: European Myasthenia Gravis Treatment Market by Treatment Type: Cholinesterase Inhibitors, Chronic Immunomodulators, Monoclonal Antibodies, Rapid Immunotherapies, Thymectomy, and Others
4.3.2: European Myasthenia Gravis Treatment Market by End Use: Hospitals, Clinics, and Others


4.4: APAC Myasthenia Gravis Treatment Market
4.4.1: APAC Myasthenia Gravis Treatment Market by Treatment Type: Cholinesterase Inhibitors, Chronic Immunomodulators, Monoclonal Antibodies, Rapid Immunotherapies, Thymectomy, and Others
4.4.2: APAC Myasthenia Gravis Treatment Market by End Use: Hospitals, Clinics, and Others


4.5: ROW Myasthenia Gravis Treatment Market
4.5.1: ROW Myasthenia Gravis Treatment Market by Treatment Type: Cholinesterase Inhibitors, Chronic Immunomodulators, Monoclonal Antibodies, Rapid Immunotherapies, Thymectomy, and Others
4.5.2: ROW Myasthenia Gravis Treatment Market by End Use: Hospitals, Clinics, and Others



5. Competitor Analysis
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis


6. Growth Opportunities and Strategic Analysis
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Myasthenia Gravis Treatment Market by Treatment Type
6.1.2: Growth Opportunities for the Global Myasthenia Gravis Treatment Market by End Use
6.1.3: Growth Opportunities for the Global Myasthenia Gravis Treatment Market by Region

6.2: Emerging Trends in the Global Myasthenia Gravis Treatment Market

6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Myasthenia Gravis Treatment Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Myasthenia Gravis Treatment Market
6.3.4: Certification and Licensing


7. Company Profiles of Leading Players
7.1: Alexion Pharmaceutical
7.2: Grifols
7.3: Avadel Pharmaceuticals
7.4: Novartis
7.5: Pfizer
7.6: AbbVie
7.7: F. Hoffmann-La Roche